CorMedix Inc. Announces New Data at ASN Kidney Week 2024
CorMedix presented new hospital admission and health economic data at ASN Kidney Week 2024, analyzing bloodstream infections (BSIs) in hemodialysis patients using central venous catheters. The study of 91,448 patients revealed that 25% were admitted with BSIs. Key findings showed median hospital stays of 16 days, with 53.8% requiring ICU care. The median total cost per admission was $157,000, with $65,000 for ICU care. The study reported 10.3% in-hospital mortality and 26.8% readmission rates within 90 days. Patient demographics showed 58.2% white, 27.1% black, with 47% from disadvantaged neighborhoods.
CorMedix ha presentato nuovi dati sulle ammissioni ospedaliere e sull'economia sanitaria durante l'ASN Kidney Week 2024, analizzando le infezioni del flusso sanguigno (BSI) nei pazienti in emodialisi che utilizzano cateteri venosi centrali. Lo studio su 91.448 pazienti ha rivelato che il 25% è stato ammesso con BSI. I risultati chiave hanno mostrato una durata mediana delle degenze ospedaliere di 16 giorni, con il 53,8% che ha richiesto assistenza in terapia intensiva (ICU). Il costo totale mediano per ammissione è stato di $157.000, con $65.000 per l'assistenza in terapia intensiva. Lo studio ha riportato una mortalità in ospedale del 10,3% e tassi di readmissione del 26,8% entro 90 giorni. La demografia dei pazienti ha mostrato il 58,2% di bianchi, il 27,1% di neri, con il 47% provenienti da quartieri svantaggiati.
CorMedix presentó nuevos datos sobre admisiones hospitalarias y economía de la salud en la ASN Kidney Week 2024, analizando infecciones en el torrente sanguíneo (BSI) en pacientes en hemodiálisis utilizando catéteres venosos centrales. El estudio de 91,448 pacientes reveló que el 25% fue admitido con BSI. Los hallazgos clave mostraron estancias hospitalarias medianas de 16 días, con el 53.8% requiriendo cuidados en UCI. El costo total mediano por admisión fue de $157,000, con $65,000 por cuidados en UCI. El estudio reportó una mortalidad interna del 10.3% y tasas de readmisión del 26.8% dentro de los 90 días. La demografía de los pacientes mostró un 58.2% de blancos, un 27.1% de negros, con un 47% provenientes de vecindarios desfavorecidos.
CorMedix는 2024 ASN Kidney Week에서 새로운 병원 입원 및 건강 경제 데이터를 발표하였으며, 중심 정맥 카테터를 사용하는 혈액투석 환자에서의 혈류 감염 (BSI)을 분석하였습니다. 91,448명의 환자를 대상으로 한 연구에서 25%가 BSI로 입원한 것으로 나타났습니다. 주요 발견 사항은 중위 병원 입원 기간이 16일이고, 53.8%가 중환자실(ICU) 치료를 필요로 한 것으로 나타났습니다. 입원당 중위 총 비용은 $157,000였고, ICU 치료에 대한 비용은 $65,000였습니다. 연구에서는 입원 중 사망률이 10.3%이고, 90일 이내의 재입원율이 26.8%로 보고되었습니다. 환자 인구 통계는 백인이 58.2%, 흑인이 27.1%이며, 47%는 저소득 지역 출신임을 보여주었습니다.
CorMedix a présenté de nouvelles données sur les admissions hospitalières et l'économie de la santé lors de l'ASN Kidney Week 2024, analysant les infections sanguines (BSI) chez les patients en hémodialyse utilisant des cathéters veineux centraux. L'étude portant sur 91 448 patients a révélé que 25% avaient été admis avec des BSI. Les résultats clés ont montré une durée médiane d'hospitalisation de 16 jours, avec 53,8% nécessitant des soins en réanimation. Le coût total médian par admission était de 157 000 $, dont 65 000 $ pour les soins en réanimation. L'étude a rapporté une mortalité hospitalière de 10,3% et des taux de réadmission de 26,8% dans les 90 jours. Les caractéristiques démographiques des patients indiquaient que 58,2% étaient blancs, 27,1% étaient noirs, et 47% provenaient de quartiers défavorisés.
CorMedix präsentierte auf der ASN Kidney Week 2024 neue Daten zu Krankenhausaufenthalten und Gesundheitsökonomie, die Blutstrominfektionen (BSIs) bei hämodialysepflichtigen Patienten mit zentralen venösen Kathetern analysieren. Die Studie mit 91.448 Patienten ergab, dass 25% mit BSIs aufgenommen wurden. Zu den wichtigsten Ergebnissen gehörten eine mittlere Aufenthaltsdauer im Krankenhaus von 16 Tagen, wobei 53,8% intensivmedizinische Betreuung benötigten. Die medianen Gesamtkosten pro Aufnahme betrugen $157.000, davon $65.000 für die Intensivpflege. Die Studie berichtete von einer In-hospital-Sterblichkeitsrate von 10,3% und einer Wiederaufnahmerate von 26,8% innerhalb von 90 Tagen. Die demografischen Daten der Patienten zeigten, dass 58,2% weiß, 27,1% schwarz waren und 47% aus benachteiligten Stadtteilen stammten.
- Study provides comprehensive data supporting the market need for CRMD's infection prevention products
- Large market opportunity demonstrated by high treatment costs ($157,000 per admission)
- High readmission rate (26.8%) indicates potential for recurring revenue
- No direct revenue or product-related announcements
- Study highlights challenges in target market with high mortality rates (10.3%)
Insights
The retrospective analysis of HD-CVC patients reveals concerning statistics that highlight a significant market opportunity for preventive solutions. With 25% of catheter patients developing bloodstream infections and a
The data strongly supports the clinical need for CorMedix's DefenCath, a catheter lock solution designed to prevent bloodstream infections. The high-risk patient profile (87.8% with multiple comorbidities) and significant ICU utilization (53.8% of admissions) suggest that preventive measures could substantially reduce healthcare costs and improve patient outcomes. This market research strengthens CorMedix's value proposition as they approach potential FDA approval.
Study highlights significant healthcare challenges and costs associated with bloodstream infections (BSIs) in patients receiving chronic hemodialysis through central venous catheters (HD-CVCs)
BERKELEY HEIGHTS, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced new hospital admission and health economic data presented at the American Society of Nephrology Kidney Week 2024 in San Diego, CA from October 24 - 27.
This retrospective analysis, using data from the Premier Healthcare Database, evaluated hospital admissions from 2020 to 2022 to examine the demographics, clinical characteristics, and outcomes of adult HD-CVC patients hospitalized for bloodstream infections (BSIs). Among the 91,448 unique patients admitted,
- Patient Demographics: The patient population was
58.2% white,27.1% black, and56.6% male, with59.3% aged 60 years or older. A substantial number of patients lived in vulnerable communities, with47% residing in the most socioeconomically disadvantaged quartile of neighborhoods nationwide. - Hospitalization Outcomes: The median length of stay for BSI-related hospitalizations was 16 days, with
53.8% of admissions involving time in the ICU (median stay: 8 days). The study reported an all-cause in-hospital mortality rate of10.3% . - Comorbidities: Patients had extensive comorbidities, with
87.8% having three or more Charlson comorbidity conditions, and42.6% had six or more. - Economic Impact: The median total cost of admission was
$157,000 , with$65,000 attributed to ICU care alone. Healthcare utilization, including readmissions (26.8% within 90 days), placed a significant financial burden resulting from these infections.
"This study underscores the critical need for improved prevention strategies and interventions in the management of catheter-related bloodstream infections (CRBSIs) among hemodialysis patients," says CorMedix CEO, Joseph Todisco. "With one in four patients admitted for a bloodstream infection and a
This poster presentation will be made available on the Company’s website at www.cormedix.com/publications-and-presentations.
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin), which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
What were the key findings of CorMedix's study presented at ASN Kidney Week 2024?
What is the economic impact of bloodstream infections in hemodialysis patients according to CRMD's study?
What patient demographics were revealed in CorMedix's 2024 ASN study?
